Your fastest route to life science investment opportunities in Norway

Bio-Medisinsk Innovasjon AS (BMI) offers you the pick of the exciting new biomedical investment opportunities coming out of Norway. We act as an investor and incubator for start-ups, cooperating closely with Medinnova, the TTO for several of the country’s leading hospitals such as Rikshospitalet-Radiumhospitalet and Ullevål University hospitals. We are also strongly linked to the Radium Hospital Research Foundation (RF) and the Oslo Cancer Cluster (OCC). For more information about our investment opportunities, go to our Projects page.

Focus

We see our prime role as reducing risk and increasing success rates for early start-ups. We aim to do this by filling the current commercial management resource gap between the TTO spinout and venture capitalist investment stages. This enables us to create a balanced product portfolio with an optimized risk/return profile; a portfolio full of opportunity for international biomedical investors.

Vision

BMI will benefit from close relations to the dominating sources of basic and applied biomedical research in Norway through a preferred partner agreement with Medinnova, and a close relationship to The Radium Hospital Research Foundation and Oslo Cancer Cluster

Fill the void between the TTO’s and Venture Capital investors

Create a balanced product portfolio with optimized risk/return profile

Recent achievement

August 2009, Nextera AS was established, based on a proprietary new phage display technology.

Nextera utilizes the pVII capsid protein of filamentous bacteriophages as a scaffold for display of peptides and proteins.